G D Maclean - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

G D Maclean

Showing results (31-40 of 45) with videos related to

Pageof 5

Sort By:

Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1996

Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamideG D MacLean, D W Miles, R D Rubens, et al.

Cancer Immunology, Immunotherapy : CII|January 1, 1990

Effective drug-antibody targeting using a novel monoclonal antibody against the proliferative compartment of mammalian squamous carcinomasL Ding, J Samuel, G D MacLean, et al.

Journal of the National Cancer Institute|March 1, 1987

Monoclonal antibodies and synthetic tumor-associated glycoconjugates in the study of the expression of Thomsen-Friedenreich-like and Tn-like antigens on human cancersB M Longenecker, D J Willans, G D MacLean, et al.

Cancer Immunology, Immunotherapy : CII|January 1, 1987

T cell recognition of a tumor-associated glycoprotein and its synthetic carbohydrate epitopes: stimulation of anticancer T cell immunity in vivoC M Henningsson, S Selvaraj, G D MacLean, et al.

International Journal of Cancer|May 16, 1995

CD69+ and HLA-DR+ activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: correlations with survival following active specific immunotherapyM B Yacyshyn, S Poppema, A Berg, et al.

Journal of Immunotherapy (Hagerstown, Md. : 1997)|January 30, 1999

Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccineB M Sandmaier, D V Oparin, L A Holmberg, et al.

International Journal of Cancer|June 17, 1998

Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptideM Reddish, G D MacLean, R R Koganty, et al.

The International Journal of Biological Markers|April 1, 1991

Clinical evaluation of a new two-site assay for CA125 antigenV Capstick, G D Maclean, M R Suresh, et al.

Cancer Immunology, Immunotherapy : CII|January 1, 1993

Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvantG D MacLean, M Reddish, R R Koganty, et al.

Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|August 19, 2000

The effects of circulating antigen on the pharmacokinetics and radioimmunoscintigraphic properties of 99m Tc labelled monoclonal antibodies in cancer patientsS A McQuarrie, T Riauka, R P Baum, et al.

Pageof 5

Search research articles

Showing results (31-40 of 45) with videos related to

Sort By:

Pageof 5

Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1996

Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamideG D MacLean, D W Miles, R D Rubens, et al.

Cancer Immunology, Immunotherapy : CII|January 1, 1990

Effective drug-antibody targeting using a novel monoclonal antibody against the proliferative compartment of mammalian squamous carcinomasL Ding, J Samuel, G D MacLean, et al.

Journal of the National Cancer Institute|March 1, 1987

Cancer Immunology, Immunotherapy : CII|January 1, 1987

T cell recognition of a tumor-associated glycoprotein and its synthetic carbohydrate epitopes: stimulation of anticancer T cell immunity in vivoC M Henningsson, S Selvaraj, G D MacLean, et al.

International Journal of Cancer|May 16, 1995

Journal of Immunotherapy (Hagerstown, Md. : 1997)|January 30, 1999

International Journal of Cancer|June 17, 1998

Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptideM Reddish, G D MacLean, R R Koganty, et al.

The International Journal of Biological Markers|April 1, 1991

Clinical evaluation of a new two-site assay for CA125 antigenV Capstick, G D Maclean, M R Suresh, et al.

Cancer Immunology, Immunotherapy : CII|January 1, 1993

Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvantG D MacLean, M Reddish, R R Koganty, et al.

Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|August 19, 2000

The effects of circulating antigen on the pharmacokinetics and radioimmunoscintigraphic properties of 99m Tc labelled monoclonal antibodies in cancer patientsS A McQuarrie, T Riauka, R P Baum, et al.

Pageof 5